Estados financieros detallados de Intensity Therapeutics, Inc. (INTS): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $3.81, INTS presenta beneficios negativos (P/E no significativo) y un ROE del -97.73%. La capitalización bursátil es de $10M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | 0 | 0 | $147000 | 0 | $26000 |
| Beneficio Bruto | 0 | 0 | 0 | 0 | -$147000 | 0 | -$26000 |
| I+D | $4.4M | $5.1M | $5.9M | $5.1M | $4.8M | $10.5M | $6.8M |
| Generales y Administrativos | $1.2M | $1.2M | $2.1M | $2.4M | $3.4M | $6.1M | $5.2M |
| Gastos Operativos | $5.7M | $6.2M | $8.0M | $7.5M | $8.2M | $16.6M | $12.0M |
| Beneficio Operativo | -$5.7M | -$6.2M | -$8.0M | -$7.5M | -$8.3M | -$16.6M | -$12.0M |
| EBITDA | -$5.2M | -$6.0M | -$7.9M | -$7.3M | -$10.1M | -$16.3M | -$11.6M |
| Gastos por Intereses | 0 | 0 | $16767 | $81781 | $305000 | 0 | 0 |
| Beneficio Antes de Impuestos | -$5.4M | -$6.0M | -$7.9M | -$7.6M | -$10.5M | -$16.3M | -$11.6M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$5.2M | -$6.0M | -$7.9M | -$7.6M | -$10.5M | -$16.3M | -$11.6M |
| BPA | $-39.50 | $-44.25 | $-58.00 | $-55.50 | $-34.50 | $-29.25 | $-8.56 |
| BPA Diluido | $-39.50 | $-44.25 | $-58.00 | $-55.50 | $-34.50 | $-29.25 | $-8.56 |
| Acciones en Circulación (Diluidas) | $136120 | $136381 | $136404 | $136404 | $344653 | $556279 | $13.6M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | -$7000 | -$7000 |
| Beneficio Operativo | -$2.7M | -$3.1M | -$2.5M | -$3.1M |
| EBITDA | $62000 | -$3.0M | -$2.4M | -$3.1M |
| Beneficio Neto | -$2.7M | -$3.1M | -$2.4M | -$3.0M |
| BPA | $-1.55 | $-1.21 | $-0.96 | $-1.11 |
| BPA Diluido | $-1.55 | $-1.21 | $-0.96 | $-1.11 |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $3.8M | $9.3M | $4.5M | $1.3M | $8.6M | $2.6M | $11.9M |
| Inversiones a Corto | $4.6M | 0 | 0 | 0 | $6.2M | 0 | 0 |
| Cuentas por Cobrar | $33634 | $48521 | $51262 | $62304 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $8.6M | $9.5M | $4.7M | $1.5M | $15.5M | $3.4M | $12.7M |
| Inmovilizado Material | $252668 | $490240 | $318126 | $139000 | $147000 | $122000 | $96000 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $9.0M | $10.1M | $5.2M | $1.8M | $17.3M | $4.8M | $14.1M |
| Cuentas por Pagar | $393963 | $222707 | $172508 | $603000 | $3.0M | $1.2M | $583000 |
| Deuda a Corto | $117194 | 0 | $2.0M | $4.3M | 0 | 0 | 0 |
| Pasivos Corrientes | $1.1M | $1.3M | $3.7M | $6.8M | $4.0M | $1.8M | $2.1M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | $79000 |
| Pasivos Totales | $1.3M | $11.7M | $13.9M | $16.9M | $4.1M | $1.9M | $2.2M |
| Reservas | 0 | -$23.2M | -$31.1M | -$38.7M | -$50.5M | -$66.8M | -$78.4M |
| Patrimonio Neto | $7.7M | -$1.6M | -$8.7M | -$15.1M | $13.2M | $2.9M | $11.9M |
| Deuda Total | $260270 | $497481 | $2.3M | $4.5M | $158000 | $138000 | $110000 |
| Deuda Neta | -$8.1M | -$8.8M | -$2.2M | $3.2M | -$14.6M | -$2.5M | -$11.8M |
| Capital Circulante | $7.5M | $8.1M | $1.0M | -$5.4M | $11.5M | $1.6M | $10.6M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $7.1M | $11.9M | $10.2M | $9.5M |
| Activos Totales | $9.6M | $14.1M | $12.3M | $11.5M |
| Pasivos Totales | $2.4M | $2.2M | $2.3M | $2.3M |
| Patrimonio Neto | $7.2M | $11.9M | $10.0M | $9.2M |
| Deuda Total | $118000 | $110000 | $102000 | $95000 |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$5.4M | -$6.0M | -$7.9M | -$7.6M | -$10.5M | -$16.3M | -$11.6M |
| Amortizaciones | 0 | 0 | 0 | $179037 | 0 | 0 | 0 |
| Compensación en Acciones | $561377 | $555488 | $719822 | $1.2M | $1.4M | $3.1M | $2.0M |
| Cambio en Capital Circulante | $306908 | -$12033 | $176801 | $756689 | -$633000 | -$2.1M | $347000 |
| Flujo de Caja Operativo | -$4.4M | -$5.4M | -$6.8M | -$5.5M | -$7.2M | -$15.2M | -$9.2M |
| Inversiones (CapEx) | 0 | 0 | $3 | 0 | 0 | 0 | 0 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$4.4M | -$5.4M | -$6.8M | -$5.5M | -$7.2M | -$15.2M | -$9.2M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$2.4M | -$2.4M | -$1.8M | -$2.3M |
| Inversiones (CapEx) | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$2.4M | -$2.4M | -$1.8M | -$2.3M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | 0 | $450000 | $387000 | $387000 |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Beneficio Neto (anual) | | -13.9% | -32.6% | +4.0% | -39.0% | -54.4% | +28.7% |
| Crecimiento BPA (anual) | | -12.0% | -31.1% | +4.3% | +37.8% | +15.2% | +70.7% |
| Cambio en Acciones (anual) | | +0.2% | +0.0% | +0.0% | +152.7% | +61.4% | +2338.3% |
| Crecimiento FCF (anual) | | -21.6% | -27.1% | +19.8% | -31.5% | -111.2% | +39.3% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-32.44 | $-39.38 | $-50.05 | $-40.16 | $-20.91 | $-27.36 | $-0.68 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $136080 | $136360 | $136400 | $136400 | $306160 | $556240 | $13.6M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -97.73% |
| Rentabilidad sobre capital invertido | -99.88% |
| Rentabilidad sobre activos | -82.31% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.01 |
| Ratio corriente | 5.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 27.84 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -3.77 | -3.37 | -2.57 | -2.68 | -6.21 | -1.50 | -1.20 |
| P/VC | 2.63 | -13.04 | -2.34 | -1.35 | 4.98 | 8.39 | 11.72 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |